COVID-19 Treatment: Eli Lilly Gets DCGI Emergency-Use Approval for Monoclonal Antibody Drugs Bamlanivimab 700 Mg and Etesevimab 1400 Mg
Eli Lilly and Co's antibody drug combination has received an emergency use approval in India. The combination of bamlanivimab 700mg and etesevimab 1,400mg, has been allowed in India for the treatment of patients with mild to moderate COVID-19.
Eli Lilly gets DCGI emergency-use approval for antibody drugs to treat COVID-19
(SocialLY brings you all the latest breaking news, viral trends and information from social media world, including Twitter, Instagram and Youtube. The above post is embeded directly from the user's social media account and LatestLY Staff may not have modified or edited the content body. The views and facts appearing in the social media post do not reflect the opinions of LatestLY, also LatestLY does not assume any responsibility or liability for the same.)